[前列腺癌的分子高通量研究] - Suppr

Suppr

超能文献

[Molecular high throughput research in prostate carcinoma].

作者信息

Schlomm T, Sültmann H, Poustka A, Sauter G, Hellwinkel O J C, Huland H

机构信息

Martini-Klinik am UKE, Universitätsklinikum Hamburg-Eppendorf, Martinistrasse 52, Gebäude O46, 20246 Hamburg.

出版信息

Urologe A. 2007 Sep;46(9):1097-100. doi: 10.1007/s00120-007-1440-4.

DOI:10.1007/s00120-007-1440-4

PMID:17628772

Abstract

摘要

相似文献

[Molecular high throughput research in prostate carcinoma].[前列腺癌的分子高通量研究]

Urologe A. 2007 Sep;46(9):1097-100. doi: 10.1007/s00120-007-1440-4.

[Organization of data and tissue banks for new prognostic factors in adenocarcinoma of the prostate. An interdisciplinary uropathologic approach].[前列腺腺癌新预后因素的数据与组织库组织。一种跨学科的泌尿病理学方法]

Urologe A. 2007 Sep;46(9):1094. doi: 10.1007/s00120-007-1439-x.

[Cytogenetic changes in prostatic carcinoma].

Pathologe. 1998 Jan;19(1):63-8. doi: 10.1007/s002920050256.

[Quantifying gene expression in prostate carcinoma. Which endogenous reference genes are suitable?].

Urologe A. 2007 Sep;46(9):1083-4. doi: 10.1007/s00120-007-1436-0.

Genomic gestalt.

Minn Med. 2005 Apr;88(4):11-2.

[Molecular characterization of metastatic renal cell carcinomas. Differentiation of prognosis and therapy].[转移性肾细胞癌的分子特征。预后与治疗的鉴别]

Urologe A. 2008 Sep;47(9):1187-9. doi: 10.1007/s00120-008-1847-6.

[Tissue microarrays. High-throughput procedures to verify potential biomarkers].[组织微阵列。验证潜在生物标志物的高通量方法]

Urologe A. 2004 Jun;43(6):659-67. doi: 10.1007/s00120-004-0576-8.

Neuroendocrine differentiation in prostate adenocarcinoma.前列腺腺癌中的神经内分泌分化

Eur Urol. 2007 Nov;52(5):1373.

[Identification and validation of clinically relevant molecular alterations in prostate cancer].[前列腺癌临床相关分子改变的鉴定与验证]

Urologe A. 2008 Sep;47(9):1193-8. doi: 10.1007/s00120-008-1834-y.

[Molecular profiling and predictive signatures. Biomarker analysis in ovarian cancer].[分子剖析与预测性特征。卵巢癌中的生物标志物分析]

Pathologe. 2008 Nov;29 Suppl 2:168-71. doi: 10.1007/s00292-008-1073-4.

引用本文的文献

[Identification and validation of clinically relevant molecular alterations in prostate cancer].[前列腺癌临床相关分子改变的鉴定与验证]

Pathologe. 2009 Mar;30(2):111-6. doi: 10.1007/s00292-008-1113-0.

[Identification and validation of clinically relevant molecular alterations in prostate cancer].[前列腺癌临床相关分子改变的鉴定与验证]

Urologe A. 2008 Sep;47(9):1193-8. doi: 10.1007/s00120-008-1834-y.

本文引用的文献

Clinical significance of epidermal growth factor receptor protein overexpression and gene copy number gains in prostate cancer.表皮生长因子受体蛋白过表达及基因拷贝数增加在前列腺癌中的临床意义

Clin Cancer Res. 2007 Nov 15;13(22 Pt 1):6579-84. doi: 10.1158/1078-0432.CCR-07-1257.

Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer.雌激素受体α（ESR1）基因扩增在乳腺癌中很常见。

Nat Genet. 2007 May;39(5):655-60. doi: 10.1038/ng2006. Epub 2007 Apr 8.

Close association between HER-2 amplification and overexpression in human tumors of non-breast origin.HER-2扩增与非乳腺来源的人类肿瘤中过表达之间的密切关联。

Mod Pathol. 2007 Feb;20(2):192-8. doi: 10.1038/modpathol.3800729.

Molecular staging of prostate cancer in the year 2007.2007年前列腺癌的分子分期

World J Urol. 2007 Mar;25(1):19-30. doi: 10.1007/s00345-007-0153-z. Epub 2007 Mar 2.

Functional profiling: from microarrays via cell-based assays to novel tumor relevant modulators of the cell cycle.功能分析：从微阵列到基于细胞的检测，再到细胞周期的新型肿瘤相关调节因子。

Cancer Res. 2005 Sep 1;65(17):7733-42. doi: 10.1158/0008-5472.CAN-05-0642.

Extraction and processing of high quality RNA from impalpable and macroscopically invisible prostate cancer for microarray gene expression analysis.从无法触及且肉眼不可见的前列腺癌中提取和处理高质量RNA用于微阵列基因表达分析。

Int J Oncol. 2005 Sep;27(3):713-20.

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.肺癌中的表皮生长因子受体（EGFR）突变：与吉非替尼治疗临床反应的相关性

Science. 2004 Jun 4;304(5676):1497-500. doi: 10.1126/science.1099314. Epub 2004 Apr 29.

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.表皮生长因子受体中的激活突变是非小细胞肺癌对吉非替尼产生反应的基础。

N Engl J Med. 2004 May 20;350(21):2129-39. doi: 10.1056/NEJMoa040938. Epub 2004 Apr 29.

Targeting HER2 in other tumor types.针对其他肿瘤类型中的HER2 。

Ann Oncol. 2001;12 Suppl 1:S81-7. doi: 10.1093/annonc/12.suppl_1.s81.

Tissue microarrays for high-throughput molecular profiling of tumor specimens.用于肿瘤标本高通量分子分析的组织微阵列。

Nat Med. 1998 Jul;4(7):844-7. doi: 10.1038/nm0798-844.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验